UNSPSC 51373103: Diethylthiambutene hydrochloride

This classification denotes an opioid receptor agonist C16H21NS2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L46E90B1X, chemically known as 3-buten-2-amine, n,n-diethyl-4,4-di-2-thienyl-, hydrochloride (1:1), but more generally known as diethylthiambutene hydrochloride, which bears US NIH Compound Identifier 8585. Most nations, for tariff and trade purposes, schedule diethylthiambutene hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, DIETHYLTHIAMBUTENE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)C(C)C=C(C1CCCS1)C2CCCS2.CL.

UNSPSC 51373103 Diethylthiambutene hydrochloride is a Commodity code that, based on recent state and local activity, does not reflect what is actually being procured under this code designation. The recent opportunities tagged to this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals — none of which are diethylthiambutene hydrochloride. The mismatch suggests either a classification error in the underlying opportunity records or that this code sees limited aligned procurement activity in the state and local market right now.

Activity appears concentrated in Florida and Minnesota, with a preliminary market intelligence phase in Texas. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and meet FDA cGMP and Drug Supply Chain Security Act compliance. The MMCAP procurement weights price competitiveness at 75 percent and mandates a 3 percent administrative fee on all purchases. No explicit set-aside designations appear in the available records.